INFLUENCE OF BEZAFIBRATE AND COLESTIPOL ON LDL-CHOLESTEROL, LDL-APOLIPOPROTEIN-B AND HDL-CHOLESTEROL IN HYPERLIPOPROTEINEMIA

被引:0
|
作者
KLOSIEWICZLATOSZEK, L
NOWICKA, G
SZOSTAK, WB
NARUSZEWICZ, M
机构
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A significant increase of LDL-apolipoprotein B by 13% and LDL-cholesterol by 19% was observed in a group of 9 patients with hyperlipoproteinaemia Type III after bezafibrate treatment. Additional administration of colestipol caused a significant decrease of both LDL-apolipoprotein B by 18% and LDL-cholesterol by 25%. In 10 patients of hyperlipoproteinaemia Type IIb a significant decrease of both LDL-apolipoprotein B by 28% and LDL-apolipoprotein B by 18% was observed after bezafibrate therapy. When bezafibrate was given together with colestipol a further decrease of both LDL-cholesterol by 17% and LDL-apolipoprotein B by 16% occurred. HDL-cholesterol concentration increased significantly in both groups of hyperlipaemic patients during therapy. This may be the effect of both bezafibrate and colestipol. It is concluded that bile acid resins may effectively prevent the LDL-cholesterol concentration increase observed sometimes after clofibrate analogues.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [1] LDL-CHOLESTEROL AND HDL-CHOLESTEROL IN CHILDREN
    SPAHN, U
    PLENERT, W
    PETRICH, E
    PEDIATRIC RESEARCH, 1981, 15 (08) : 1199 - 1199
  • [2] DETERMINATION OF HDL-CHOLESTEROL AND LDL-CHOLESTEROL BY CHOLESTEROL DEHYDROGENASE
    URATA, T
    SAKURABAYASHI, I
    KAWAI, T
    CLINICAL CHEMISTRY, 1983, 29 (06) : 1173 - 1174
  • [4] LDL-cholesterol, HDL-cholesterol or triglycerides - which is the culprit?
    Taskinen, MR
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 61 : S19 - S26
  • [5] Standardization of Apolipoprotein B, LDL-Cholesterol, and Non-HDL-Cholesterol
    Contois, John H.
    Langlois, Michel R.
    Cobbaert, Christa
    Sniderman, Allan D.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (15):
  • [6] LDL-cholesterol and HDL-cholesterol concentrations decrease during the day
    Miida, T
    Nakamura, Y
    Mezaki, T
    Hanyu, O
    Maruyama, S
    Horikawa, Y
    Izawa, S
    Yamada, Y
    Matsui, H
    Okada, M
    ANNALS OF CLINICAL BIOCHEMISTRY, 2002, 39 : 241 - 249
  • [7] Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention
    Parhofer, KG
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (08) : 414 - 417
  • [8] CordyMax reduces serum oxidized LDL-cholesterol and increases HDL-cholesterol in humans with reduced HDL-cholesterol
    Zhu, JS
    Pei, Y
    Xu, ZB
    Wang, BE
    Rippe, J
    CIRCULATION, 2003, 108 (17) : 781 - 781
  • [10] CETP is a determinant of serum LDL-cholesterol but not HDL-cholesterol in healthy Japanese
    Kinoshita, M
    Teramoto, T
    Shimazu, N
    Kaneko, K
    Ohta, M
    Koike, T
    Hosogaya, S
    Ozaki, Y
    Kume, S
    Yamanaka, M
    ATHEROSCLEROSIS, 1996, 120 (1-2) : 75 - 82